Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics


Sol-Gel Technologies Ltd. (SLGL)

Today's Latest Price: $8.42 USD

0.12 (-1.41%)

Updated Oct 23 6:55pm

Add SLGL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SLGL Stock Summary

  • With a one year PEG ratio of 0.2, Sol-Gel Technologies Ltd is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 4.26% of US stocks.
  • With a year-over-year growth in debt of -96.87%, Sol-Gel Technologies Ltd's debt growth rate surpasses merely 1.38% of about US stocks.
  • Revenue growth over the past 12 months for Sol-Gel Technologies Ltd comes in at 13,063.22%, a number that bests 99.86% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sol-Gel Technologies Ltd are LIFE, ZLAB, IMMU, CRSP, and CLSD.
  • Visit SLGL's SEC page to see the company's official filings. To visit the company's web site, go to www.sol-gel.com.

SLGL Stock Price Chart Interactive Chart >

Price chart for SLGL

SLGL Price/Volume Stats

Current price $8.42 52-week high $21.00
Prev. close $8.54 52-week low $5.00
Day low $8.25 Volume 3,200
Day high $8.43 Avg. volume 42,113
50-day MA $7.69 Dividend yield N/A
200-day MA $8.66 Market Cap 171.68M

Sol-Gel Technologies Ltd. (SLGL) Company Bio


Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel


SLGL Latest News Stream


Event/Time News Detail
Loading, please wait...

SLGL Latest Social Stream


Loading social stream, please wait...

View Full SLGL Social Stream

Latest SLGL News From Around the Web

Below are the latest news stories about Sol-Gel Technologies Ltd that investors may wish to consider to help them evaluate SLGL as an investment opportunity.

Sol Gel Technologies (SLGL) Presents At H. C. Wainwright 22nd Annual Global Investment Conference - Slideshow

The following slide deck was published by Sol-Gel Technologies Ltd. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 17, 2020

Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammatory Lesions of Rosacea

- PDUFA Goal Date Set for April 26, 2021 - Potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product NESS ZIONA, Israel,…

GlobeNewswire | September 10, 2020

Sol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates

Sol-Gel Technologies, Ltd. (SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that it has entered into collaborative agreements with Perrigo Company plc (“Perrigo”) (NYSE; TASE: PRGO), for the development, manufacturing and commercialization of three new, generic product candidates. Consistent with Sol-Gel’s prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration (“FDA”) for these generic product candidates.

Yahoo | June 29, 2020

Sol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

NESS ZIONA, Israel, June 16, 2020 -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying,.

Yahoo | June 16, 2020

Sol-Gel Technologies Ltd. (SLGL): Hedge Funds In Wait-and-See Mode

In this article we will check out the progression of hedge fund sentiment towards Sol-Gel Technologies Ltd. (NASDAQ:SLGL) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

Yahoo | June 4, 2020

Read More 'SLGL' Stories Here

SLGL Price Returns

1-mo 15.50%
3-mo 13.78%
6-mo -0.94%
1-year 5.65%
3-year N/A
5-year N/A
YTD -50.90%
2019 184.88%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching SLGL

Want to see what other sources are saying about Sol-Gel Technologies Ltd's financials and stock price? Try the links below:

Sol-Gel Technologies Ltd (SLGL) Stock Price | Nasdaq
Sol-Gel Technologies Ltd (SLGL) Stock Quote, History and News - Yahoo Finance
Sol-Gel Technologies Ltd (SLGL) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8495 seconds.